New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:26 EDTOMEROmeros shares oversold, secondary endpoint met, says Maxim
Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
16:23 EDTOMEROmeros sees FY15 OpEx $110M-$120M
For 2015, the company anticipates that operating expenses will be in the $110M-$120M range with non-cash expenses of approximately $15M. This guidance is largely based on the continued preparations for the full-scale U.S. launch of Omidria as well as the continued development of the company's product pipeline.
16:22 EDTOMEROmeros reports Q4 EPS (61c) with items, consensus (62c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use